Evidence map›Paper›PMID 33504523›Full record

ArticleBMJ case reports2021

Optic neuropathy secondary to perhexiline and amiodarone.

Yiran Tan, Paul Sia, Sumu Simon

Open access · greenAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Risk Factors of Eye Complications in Patients Treated in the Intensive Care Unit.International journal of environmental research and public health · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yiran TanSouth Australian Institute of Ophthalmology, Royal Adelaide Hospital, Adelaide, South Australia, Australia ian.tan1100@gmail.com.
Paul SiaSouth Australian Institute of Ophthalmology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Sumu SimonSouth Australian Institute of Ophthalmology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Royal Adelaide Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bilateral optic disc swelling is an important clinical sign for potentially life-threatening and sight-threatening conditions, with the most common being raised intracranial pressure and pseudopapillitis. Perhexiline-related and amiodarone-related optic disc swellings are diagnoses of exclusion. This report describes the diagnosis of a man with perhexiline-induced and amiodarone-induced optic neuropathy after extensive investigation consisting of full ophthalmic examination, biochemical screen, temporal artery biopsy, CT, MRI, positron emission tomography and lumbar puncture. There was partial to complete resolution of optic neuropathy following cessation of the causative medication. We postulate that the underlying mechanism of perhexiline toxicity could be mitochondrial dysfunction related. Our case demonstrates that patients treated with perhexiline and amiodarone should be monitored closely for ocular side effects.

Indexed as

AgedAmiodaroneFluorescein AngiographyHumansMaleOptic Nerve DiseasesPerhexilineRecurrenceTomography, Optical CoherenceVasodilator AgentsAmiodaronePerhexilineVasodilator Agentscardiovascular systemneuroopthalmologyunwanted effects / adverse reactions

Identifiers

PMID33504523
PMCPMC7843302
OpenAlexW3121787264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.